AndroGel (Testosterone Topical) Transfer to Women and Children: When It Doesn't Go Away

Why AndroGel Transfer Happens in the First Place

Testosterone gel is applied to skin, and a meaningful fraction of each dose sits on the surface before percutaneous absorption is complete. Skin-to-skin contact during that window transfers enough testosterone to produce measurable serum elevations in exposed individuals. The FDA added a black-box warning to all testosterone topical products in 2009 specifically because of pediatric virilization cases reported through the Adverse Event Reporting System (FAERS) [1].

The Absorption Timeline

After a standard 5 g dose of 1% AndroGel, roughly 10% (50 mg) is absorbed transdermally over 24 hours [2]. The remaining residue does not disappear instantly. Studies using radiolabeled testosterone show detectable surface activity for up to 2 hours post-application on unwashed skin [2]. Clothing contact during that window transfers residue to fabric, which can then act as a secondary reservoir.

Why Women and Children Are at Greater Risk

Men using AndroGel already have baseline serum testosterone in the 300 to 1,000 ng/dL range, so an incidental skin transfer adds a smaller relative change. Women typically have serum testosterone below 70 ng/dL, and prepubertal children have levels near or below 10 ng/dL [3]. A transfer event that delivers even 1 to 2 mg of additional testosterone can double or triple their circulating androgen load. The endocrine system of a young child has no tolerance buffer.

What FAERS Data Show

Between 2000 and 2009, the FDA identified at least 20 pediatric cases of secondary exposure virilization linked to testosterone topical products, prompting the 2009 label revision [1]. A 2010 review in Pediatrics documented clitoral enlargement, pubic hair growth, and advanced bone age in children aged 9 months to 5 years after household contact with adult male users [4]. Bone-age advancement is particularly concerning because it can permanently reduce adult height potential.

What "When It Doesn't Go Away" Actually Means Clinically

Most physicians expect signs of androgen excess to reverse within a few weeks once exposure stops. When they don't, there are usually three explanations: the exposure hasn't actually stopped, the duration of prior exposure was long enough to advance bone age irreversibly, or the patient has an underlying sensitivity that amplifies androgenic effects.

Signs That Should Trigger Urgent Evaluation

In children, any of the following warrant same-week pediatric endocrinology referral:

• Clitoral or penile enlargement
• Pubic or axillary hair in a child under 8 years
• Accelerated linear growth or advanced bone age on wrist X-ray
• Acne in a child under 8 years
• Voice deepening

In women, persistent symptoms include acne that doesn't respond to standard topical therapy, new or worsening hirsutism, clitoral sensitivity changes, and menstrual irregularity. A serum total testosterone above 70 ng/dL in a premenopausal woman with no known endogenous cause should prompt immediate investigation into environmental androgen exposure [3].

Why Symptoms Persist After Exposure Ends

Testosterone exerts genomic effects by binding the androgen receptor and altering gene transcription. Once receptor-mediated changes occur in target tissues (hair follicles, clitoris, laryngeal cartilage, bone growth plates), those changes don't reverse simply because circulating testosterone normalizes. Pubic hair acquired through androgen exposure does not shed immediately. Clitoral tissue that has enlarged may partially regress but rarely returns to the pre-exposure baseline without months of androgen-free time. Bone-age advancement is irreversible once growth plate fusion accelerates [4].

The HealthRX clinical team uses a three-tier classification for persistent secondary exposure:

Tier 1 (Resolved within 4 to 8 weeks): Acne, skin oiliness, libido change in women. These are receptor-mediated but in highly reversible tissues.

Tier 2 (Resolved within 3 to 6 months): Hirsutism, menstrual irregularity, mild clitoral sensitivity changes. Follicular androgen receptors require sustained low-androgen signaling to normalize.

Tier 3 (Partially or never resolved): Bone-age advancement, significant clitoral or penile enlargement, laryngeal changes, established central precocious puberty. These require specialist intervention and may cause permanent anatomical change.

Managing Ongoing or Unresolved AndroGel Transfer

Stopping the exposure is step one, but it is rarely sufficient on its own when symptoms have persisted for more than 4 weeks.

Step 1: Confirm and Eliminate the Exposure Source

Ask the male user for a detailed application log. Common overlooked transfer routes include:

• Sharing a bed or couch shortly after application
• Skin contact during exercise or in warm environments (sweat increases surface transfer)
• Children sitting on the user's lap or being carried against the application site
• Laundering the user's application-site clothing with family clothing (testosterone can bind to fabric)

Application sites on AndroGel 1.62% include the upper arms and shoulders [2]. Switching to a site covered by a shirt dramatically reduces incidental contact. The FDA label instructs users to wash hands immediately after application and cover the site with clothing before contact with others [2].

Step 2: Re-Evaluate the TRT Delivery Route

If transfer has already caused documented virilization, continuing topical testosterone in the same household is difficult to justify. The prescribing physician should discuss:

• Intramuscular testosterone cypionate or enanthate: No transfer risk after injection. Testosterone cypionate 100 to 200 mg every 1 to 2 weeks, or enanthate at similar dosing, eliminates any secondary skin exposure [5].
• Subcutaneous testosterone cypionate: Weekly or biweekly dosing at 50 to 100 mg provides stable serum levels with no topical residue.
• Testosterone pellets: Inserted subcutaneously every 3 to 6 months, no daily application, zero transfer risk.
• Nasal testosterone gel (Natesto): Applied inside the nostril, which dramatically limits skin-surface exposure compared to body-site gels [6].

The American Urological Association (AUA) guideline on testosterone deficiency states: "Clinicians should counsel patients on the potential for secondary transfer with topical testosterone formulations and discuss alternative delivery methods when household members, particularly women and children, are at risk" [5].

Step 3: Laboratory Monitoring of Exposed Individuals

Any woman or child with symptoms should have a serum total testosterone drawn. Reference ranges matter:

• Adult women (premenopausal): 15 to 70 ng/dL [3]
• Prepubertal children (either sex): typically <10 ng/dL [3]
• Pubescent females (Tanner 2 to 5): 7 to 75 ng/dL [3]

A level above 70 ng/dL in a prepubertal child with no identifiable endogenous cause is a medical emergency. ACTH-stimulated cortisol, 17-hydroxyprogesterone, and DHEA-S should be measured to exclude congenital adrenal hyperplasia before attributing the elevation solely to AndroGel transfer, but environmental exposure should be considered first when the history supports it [4].

Step 4: Specialist Referral Timelines

• Pediatric endocrinology: Within 1 week if bone age is unknown in a symptomatic child; same day if rapid virilization or penile/clitoral enlargement is acutely progressing.
• Reproductive endocrinology: Within 2 to 4 weeks for women with persistent menstrual disruption or testosterone above 70 ng/dL.
• Dermatology: Reasonable if hirsutism is the dominant complaint in a woman whose testosterone has normalized but follicular changes persist.

Long-Term Outcomes and What the Literature Says

The 2010 Pediatrics case series is the most frequently cited document on outcomes [4]. Among the 20 children with confirmed secondary testosterone exposure, all showed some improvement in soft-tissue signs (acne, oiliness, pubic hair color) after exposure stopped, but bone-age advancement was only partially reversible. In three children who had advanced bone ages of 2 or more years beyond chronological age, predicted adult height was reduced by 3 to 5 cm compared to mid-parental height calculations.

A 2020 FAERS analysis published in Drug Safety identified 127 unique pediatric adverse event reports linked to testosterone topical products between 2009 and 2018 [7]. After the FDA's 2009 black-box warning, report frequency dropped by approximately 38% in the subsequent 3-year window, likely reflecting prescriber education and improved labeling. The drop was not sustained past 2013, suggesting that label warnings alone are insufficient for long-term prevention [7].

For women, persistent androgenic alopecia following secondary testosterone exposure is documented anecdotally but lacks large controlled studies. Case reports in JAMA Dermatology describe female-pattern hair thinning that did not fully reverse at 12 months after exposure cessation in women who had experienced 6 or more months of repeated contact [8]. The androgen-sensitive follicles in the frontotemporal scalp appear to undergo miniaturization that is not fully reversible without anti-androgen therapy such as spironolactone 50 to 100 mg daily [8].

Special Situations: Pregnancy and Breastfeeding

Pregnant women exposed to exogenous testosterone face a distinct risk profile. Fetal virilization of female fetuses can occur with supraphysiologic maternal androgen exposure, particularly in the first trimester when external genitalia are differentiating [9]. The FDA classifies testosterone as Pregnancy Category X, meaning the risks clearly outweigh any potential benefit [2].

What to Do If a Pregnant Woman Had Secondary Exposure

1. Quantify the exposure: how many contact events, over what duration, at what gestational age.
2. Draw maternal serum testosterone immediately.
3. Obstetric-maternal fetal medicine (MFM) consultation if maternal testosterone exceeds 70 ng/dL or if exposure occurred before 14 weeks gestation.
4. Fetal anatomic survey ultrasound at 18 to 20 weeks to assess external genitalia in a female fetus.

No intervention exists to reverse in-utero androgen exposure once it has occurred, which makes prevention the only reliable strategy [9].

Preventing Transfer: The Evidence-Based Protocol

The FDA label for AndroGel 1.62% specifies the following after application [2]:

1. Allow the gel to dry completely (approximately 5 minutes).
2. Cover the application site with clothing.
3. Wash hands with soap and water immediately.
4. If skin-to-skin contact with another person is expected, wash the application site with soap and water before contact.

A controlled pharmacokinetic study (N=14 couples) published in Clinical Endocrinology showed that covering the application site with a cotton t-shirt reduced testosterone transfer to a female partner by 95% compared to uncovered skin [10]. Washing the application site before contact reduced transfer to below the limit of quantification in all 14 pairs [10]. These two steps (cover and wash before contact) are the most effective behavioral interventions available.

Timing Matters

The same study measured transfer at 2, 4, and 6 hours post-application. At 2 hours without washing, mean testosterone transferred to the female partner's serum was 36 ng/dL above baseline. At 6 hours without washing, the figure dropped to 12 ng/dL above baseline, indicating progressive absorption over time [10]. Families should treat the first 2 hours post-application as the highest-risk window.

Reporting, Documentation, and Medicolegal Considerations

Any confirmed case of secondary virilization from AndroGel should be reported to FDA MedWatch. The online reporting form is at fda.gov/safety/medwatch. Clinicians should document:

• Date symptoms were first noticed
• Duration and frequency of contact with the AndroGel user
• Application site and hygiene practices of the user
• Serum testosterone levels in the exposed individual with collection dates
• Any imaging (bone age X-ray) results

This documentation matters not only for clinical care but also for FAERS surveillance, which drives future label revisions and prescriber alerts.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "Physicians prescribing testosterone gels must inform patients about the risk of secondary exposure and document that this counseling occurred" [11]. Failure to counsel is the most commonly cited prescribing gap in secondary-exposure cases reviewed in FAERS narratives.